Myo-inositol is a carbocyclic sugar and a key second messenger in insulin signaling. It has become a FIRST-LINE treatment for PCOS (polycystic ovary syndrome) in Europe, where multiple guidelines now recommend it before metformin. Our research shows strong evidence: a 2012 Cochrane-quality review found 4g/day improved ovulation rate by 65%, reduced testosterone, and improved insulin sensitivity in PCOS women. It also has moderate evidence for anxiety/panic disorder (18g/day — comparable to SSRIs in one study) and gestational diabetes prevention. The 40:1 ratio of myo-inositol to D-chiro-inositol (mimicking the body's natural ratio) is the most clinically supported formulation.
Myo-inositol is a second messenger in the insulin signaling cascade. After insulin binds its receptor, a phospholipase cleaves phosphatidylinositol → inositol phosphoglycans (IPGs) → which activate downstream insulin signals (GLUT4 translocation, glycogen synthesis). In PCOS, this pathway is impaired — excess insulin is produced to compensate (hyperinsulinemia), which stimulates ovarian androgen production (testosterone, causing acne, hirsutism, anovulation). Supplemental myo-inositol restores insulin sensitivity → reduces compensatory hyperinsulinemia → reduces ovarian androgen production → restores ovulation. For anxiety: myo-inositol is the precursor to phosphatidylinositol, which is required for serotonin receptor (5-HT2) signaling — explaining the anti-anxiety effect at high doses.
No critical interactions identified.
Reviewed by the Scan Dose Research Team and Clinical Advisory Board | Last updated:
Not medical advice. Based on published clinical research and systematic reviews.